Antisense gets a grip on miR-122 in chimpanzees

Science Translational Medicine

Volumn 2, Issue 13, 2010, Pages

  Branch, Andrea D ^a   Rice, Charles M ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; MICRORNA; MICRORNA 122; MIRAVIRSEN; PEGINTERFERON; PLACEBO; POLYPROTEIN; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ANEMIA; ANTIVIRAL ACTIVITY; BODY WEIGHT; CHIMPANZEE; CHOLESTEROL BLOOD LEVEL; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG USE; GENE EXPRESSION REGULATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOCOMPROMISED PATIENT; LIVER CANCER; LIVER CIRRHOSIS; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RNA BINDING; SHORT SURVEY; TREATMENT DURATION; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; BASE SEQUENCE; CHOLESTEROL; CLINICAL TRIALS AS TOPIC; GENETIC TECHNIQUES; GENOME; HUMANS; LIVER; MICRORNAS; MOLECULAR SEQUENCE DATA; NUCLEIC ACID CONFORMATION; OLIGONUCLEOTIDES, ANTISENSE; PAN TROGLODYTES; PHOSPHOROTHIOATE OLIGONUCLEOTIDES;

EID: 77952983901     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000605     Document Type: Short Survey

References (20)

1. R. E. Lanford, E. S. Hildebrant-Eriksen, A. Petri, R. Persson, M. Lindow, M. E. Munk, S. Kauppinen, H. Orum, Therapeutic silencing of microRNA-122 in primates with chronic HCV infection. Science, 3 December 2009 (10.1126/science. 1178178).
2. H. Farnik, U. Mihm, S. Zeuzem, Optimal therapy in genotype 1 patients. Liver Int. 29 (suppl. 1), 23-30 (2009).
3. T. Asselah, Y. Benhamou, P. Marcellin, Protease and polymerase inhibitors for the treatment of hepatitis C. Liver Int. 29 (suppl. 1), 57-67 (2009).
4. S. L. Fishman, A. D. Branch, The quasispecies nature and biological implications of the hepatitis C virus. Infect. Genet. Evol. 9, 1158-1167 (2009).
5. C. L. Jopling, M. Yi, A. M. Lancaster, S. M. Lemon, P. Sarnow, Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309, 1577-1581 (2005).
6. J. I. Henke, D. Goergen, J. Zheng, Y. Song, C. G. Schüttler, C. Fehr, C. Jünemann, M. Niepmann, microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J. 27, 3300-3310 (2008).
7. C. L. Jopling, S. Schütz, P. Sarnow, Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe 4, 77-85 (2008).
8. J. Ye, Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus. PLoS Pathog. 3, e108 (2007).
9. S. B. Kapadia, F. V. Chisari, Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc. Natl. Acad. Sci. U.S.A. 102, 2561-2566 (2005).
10. J. Elmén, M. Lindow, S. Schütz, M. Lawrence, A. Petri, S. Obad, M. Lindholm, M. Hedtjärn, H. F. Hansen, U. Berger, S. Gullans, P. Kearney, P. Sarnow, E. M. Straarup, S. Kauppinen, LNA-mediated microRNA silencing in non-human primates. Nature 452, 896-899 (2008).
11. E. E. Swayze, A. M. Siwkowski, E. V. Wancewicz, M. T. Migawa, T. K. Wyrzykiewicz, G. Hung, B. P. Monia, C. F. Bennett, Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res. 35, 687-700 (2007).
12. J. Elmén, M. Lindow, A. Silahtaroglu, M. Bak, M. Christensen, A. Lind-Thomsen, M. Hedtjärn, J. B. Hansen, H. F. Hansen, E. M. Straarup, K. McCullagh, P. Kearney, S. Kauppinen, Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 36, 1153-1162 (2008).
13. S. Harrison, L. Rossaro, K.-Q. Hu, K. Patel, H. L. Tillmann, S. Dhaliwal, D. M. Torres, K. Koury, V. Goteti, C. A. Brass, S. Noviello, J. K. Albrecht, J. G. McHutchison, M. S. Sulkowski, Relationship of the use of statins and elevated lowdensity lipoprotein (LDL) or total cholesterol to virologic response in patients treated for HCV in the IDEAL study. Hepatology 50 (suppl. 4), 360A (2009).
14. M. Sarasin-Filipowicz, J. Krol, I. Markiewicz, M. H. Heim, W. Filipowicz, Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat. Med. 15, 31-33 (2009).
15. G. B. Mulamba, A. Hu, R. F. Azad, K. P. Anderson, D. M. Coen, Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922). Antimicrob. Agents Chemother. 42, 971-973 (1998).
16. D. Ge, J. Fellay, A. J. Thompson, J. S. Simon, K. V. Shianna, T. J. Urban, E. L. Heinzen, P. Qiu, A. H. Bertelsen, A. J. Muir, M. Sulkowski, J. G. McHutchison, D. B. Goldstein, Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399-401 (2009).
17. Y. Tanaka, N. Nishida, M. Sugiyama, M. Kurosaki, K. Matsuura, N. Sakamoto, M. Nakagawa, M. Korenaga, K. Hino, S. Hige, Y. Ito, E. Mita, E. Tanaka, S. Mochida, Y. Murawaki, M. Honda, A. Sakai, Y. Hiasa, S. Nishiguchi, A. Koike, I. Sakaida, M. Imamura, K. Ito, K. Yano, N. Masaki, F. Sugauchi, N. Izumi, K. Tokunaga, M. Mizokami, Genomewide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41, 1105-1109 (2009).
18. V. Suppiah, M. Moldovan, G. Ahlenstiel, T. Berg, M. Weltman, M. L. Abate, M. Bassendine, U. Spengler, G. J. Dore, E. Powell, S. Riordan, D. Sheridan, A. Smedile, V. Fragomeli, T. Müller, M. Bahlo, G. J. Stewart, D. R. Booth, J. George, IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 41, 1100-1104 (2009).
19. M. L. Volk, R. Tocco, S. Saini, A. S. Lok, Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 50, 1750-1755 (2009).
20. J. Ji, J. Shi, A. Budhu, Z. Yu, M. Forgues, S. Roessler, S. Ambs, Y. Chen, P. S. Meltzer, C. M. Croce, L. X. Qin, K. Man, C. M. Lo, J. Lee, I. O. Ng, J. Fan, Z. Y. Tang, H. C. Sun, X. W. Wang, MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med. 361, 1437-1447 (2009).